Global Blood Therapeutics (GBT) Set to Announce Earnings on Monday
Global Blood Therapeutics (GBT) Set to Announce Earnings on Monday
Global Blood Therapeutics (NASDAQ:GBT – Get Rating) is scheduled to release its earnings data after the market closes on Monday, August 8th. Analysts expect Global Blood Therapeutics to post earnings of ($1.19) per share for the quarter. Individual that are interested in registering for the company's earnings conference call can do so using this link.
全球血液治療公司(納斯達克代碼：GBT-GET Rating)定於8月8日(星期一)收盤後發佈收益數據。分析師預計，全球血液治療公司本季度每股收益將達到1.19美元。有興趣註冊參加公司收益電話會議的個人可以使用此鏈接進行註冊。
Global Blood Therapeutics (NASDAQ:GBT – Get Rating) last posted its quarterly earnings results on Wednesday, May 4th. The company reported ($1.26) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.03. The company had revenue of $55.20 million for the quarter, compared to the consensus estimate of $56.13 million. Global Blood Therapeutics had a negative net margin of 146.82% and a negative return on equity of 129.74%. The firm's revenue was up 41.5% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.21) EPS. On average, analysts expect Global Blood Therapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.
全球血液治療公司(納斯達克代碼：GBT-GET評級)最近一次公佈季度收益是在5月4日星期三。該公司公佈本季度每股收益(1.26美元)，比普遍預期的(1.29美元)高出0.03美元。該公司本季度營收為5520萬美元，而市場普遍預期為5613萬美元。環球血液治療公司的淨利潤率為負146.82%，淨資產回報率為負129.74%。與去年同期相比，該公司的收入增長了41.5%。去年同期，該公司公佈的每股收益為1.21美元。分析師平均預計，全球血液治療公司本財年每股收益為-5美元，下一財年為-3美元。
Global Blood Therapeutics Trading Up 33.0 %
全球血液治療藥物交易上漲33.0%
GBT stock opened at $63.84 on Friday. The company has a market capitalization of $4.16 billion, a PE ratio of -13.11 and a beta of 0.83. Global Blood Therapeutics has a 12 month low of $21.65 and a 12 month high of $73.02. The firm's 50-day moving average is $31.23 and its 200 day moving average is $30.75. The company has a debt-to-equity ratio of 4.34, a current ratio of 8.52 and a quick ratio of 7.74.
GBT股票週五開盤報63.84美元。該公司市值為41.6億美元，市盈率為-13.11，貝塔係數為0.83。全球血液治療公司的12個月低點為21.65美元，12個月高位為73.02美元。該公司的50日移動均線切入位在31.23美元，200日移動均線切入位在30.75美元。該公司的債務權益比為4.34，流動比率為8.52，速動比率為7.74。
Insider Buying and Selling
內幕買賣
Institutional Trading of Global Blood Therapeutics
全球血液治療的制度性交易
Several institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in Global Blood Therapeutics by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 6,024,262 shares of the company's stock valued at $208,680,000 after acquiring an additional 31,120 shares during the period. State Street Corp lifted its stake in Global Blood Therapeutics by 9.0% during the 1st quarter. State Street Corp now owns 3,456,012 shares of the company's stock valued at $119,716,000 after acquiring an additional 284,877 shares during the period. Goldman Sachs Group Inc. lifted its stake in Global Blood Therapeutics by 48.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,833,720 shares of the company's stock valued at $63,520,000 after acquiring an additional 595,983 shares during the period. Polar Capital Holdings Plc lifted its stake in shares of Global Blood Therapeutics by 19.0% in the 1st quarter. Polar Capital Holdings Plc now owns 1,095,810 shares of the company's stock valued at $37,959,000 after purchasing an additional 175,000 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Global Blood Therapeutics by 26.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 530,693 shares of the company's stock valued at $18,384,000 after purchasing an additional 111,130 shares during the period.
幾家機構投資者和對衝基金最近買賣了該公司的股票。先鋒集團(Vanguard Group Inc.)在第一季度增持了全球血液治療公司0.5%的股份。先鋒集團在此期間增持了31,120股，目前持有6,024,262股該公司股票，價值208,680,000美元。道富集團在第一季度增持了全球血液治療公司9.0%的股份。道富集團在此期間增持了284,877股，目前擁有3,456,012股該公司股票，價值119,716,000美元。高盛股份有限公司在第一季度增持了環球血液治療公司48.2%的股份。高盛股份有限公司在此期間增持了595,983股，目前持有1,833,720股該公司股票，價值63,520,000美元。極地資本控股公司在第一季度增持了全球血液治療公司19.0%的股份。Polal Capital Holdings Plc現在擁有1,095,810股該公司的股票，價值37,959,000美元，在此期間又購買了175,000股。最後，Dimension Fund Advisors LP在第一季度增持了全球血液治療公司的股份26.5%。Dimension Fund Advisors LP在此期間額外購買了111,130股票，現在擁有530,693股該公司的股票，價值18,384,000美元。
Analyst Upgrades and Downgrades
分析師升級和下調評級
Several research analysts recently commented on the stock. Wedbush set a $74.00 price target on shares of Global Blood Therapeutics in a research note on Monday, June 20th. StockNews.com raised shares of Global Blood Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 5th. Cantor Fitzgerald initiated coverage on shares of Global Blood Therapeutics in a research report on Thursday, April 28th. They issued a "buy" rating and a $75.00 price objective on the stock. Oppenheimer cut their price objective on shares of Global Blood Therapeutics from $86.00 to $71.00 in a research report on Thursday, May 5th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Global Blood Therapeutics from $39.00 to $36.00 and set a "neutral" rating on the stock in a research report on Tuesday, June 28th. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $61.40.
幾位研究分析師最近對該股發表了評論。韋德布什在6月20日星期一的一份研究報告中為全球血液治療公司的股票設定了74.00美元的目標價。在5月5日星期四的一份研究報告中，StockNews.com將全球血液治療公司的股票評級從“賣出”上調至“持有”。康託·菲茨傑拉德在4月28日星期四的一份研究報告中發起了對全球血液治療公司股票的報道。他們對該股的評級為“買入”，目標價為75美元。奧本海默在5月5日星期四的一份研究報告中將全球血液治療公司的股票目標價從86.00美元下調至71.00美元。最後，摩根大通在6月28日星期二的一份研究報告中將全球血液治療公司的股票目標價從39.00美元下調至36.00美元，並將該股的評級定為“中性”。三位研究分析師對該股的評級為持有，八位分析師對該公司股票的評級為買入。根據MarketBeat.com的數據，該公司目前的共識評級為“適度買入”，共識目標價為61.40美元。
About Global Blood Therapeutics
關於全球血液治療公司
(Get Rating)
(獲取評級)
Global Blood Therapeutics, Inc, a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
全球血液治療公司是一家生物製藥公司，致力於發現、開發和提供針對服務不足的鐮狀細胞疾病(SCD)患者羣體的治療方法。該公司提供Oxbryta片劑，這是一種治療SCD的口服藥物，每天一次。它還在第二階段對青少年和兒童SCD患者的臨牀試驗中評估了單劑和多劑Oxbryta的安全性和藥代動力學。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Global Blood Therapeutics (GBT)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc's Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It's Cheap
- Why Apple Could Be At All-Time Highs By Year End
- 免費獲取StockNews.com關於全球血液治療(GBT)的研究報告
- MarketBeat：回顧中的一週8/1-8/5
- 如何利用高貝塔係數股票最大化你的投資利潤
- 克羅諾斯集團(Cronos Group Inc.)營收上升，是時候收購了嗎？
- Beyond Meat不是沒有希望，而且它很便宜
- 蘋果為何可能在年底創下歷史新高
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《全球血液治療日報》的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對全球血液治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。
譯文內容由第三人軟體翻譯。